Vinge has advised Industrifonden and Investinor in connection with a sale of in total approximately 2,300,000 shares in Calliditas Therapeutics AB (publ) to two investors for a total value of approximately USD 17,000,000.
Calliditas is listed on Nasdaq Stockholm and focuses on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization efforts.
Vinge’s team consisted of Dain Hård Nevonen, Sofie Bjärtun, Nils Fredrik Dehlin and Hampus Olsson.
